ArticleLancet (London, England)2018
A new powerful drug to combat river blindness.
Article in Lancet (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Economic Evaluation of Oral Ivermectin, Alone or in Combination with Permethrin, versus Permethrin, in the Treatment of Classic Scabies in the Philippine Setting.Acta medica Philippina · 2025Article
- The Impact of Onchocerciasis Elimination Measures in Africa: A Systematic Review.Tropical medicine and infectious disease · 2024Review
- Presumed Onchocerciasis Chorioretinitis Spilling over into North America, Europe and Middle East.Diagnostics (Basel, Switzerland) · 2023Article
- A global call for action to tackle skin-related neglected tropical diseases (skin NTDs) through integration: An ambitious step change.PLoS neglected tropical diseases · 2023Article
- Supporting Drug Development for Neglected Tropical Diseases Using Mathematical Modeling.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Article
- Solvatomorphism of Moxidectin.Molecules (Basel, Switzerland) · 2021Article
- Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis.PLoS neglected tropical diseases · 2021Article
- Why onchocerciasis transmission persists after 15 annual ivermectin mass drug administrations in South-West Cameroon.BMJ global health · 2021Article
- Reaching the last mile: main challenges relating to and recommendations to accelerate onchocerciasis elimination in Africa.Infectious diseases of poverty · 2019Review
- Identification and characterization of the Onchocerca volvulus Excretory Secretory Product Ov28CRP, a putative GM2 activator protein.PLoS neglected tropical diseases · 2019Article
Corrections and comments
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
29361336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.